...
首页> 外文期刊>Trends in Cardiovascular Medicine >Thymidine phosphorylase: A potential new target for treating cardiovascular disease
【24h】

Thymidine phosphorylase: A potential new target for treating cardiovascular disease

机译:胸苷磷酸化酶:一种治疗心血管疾病的潜在新靶标

获取原文
获取原文并翻译 | 示例
           

摘要

We recently found that thymidine phosphorylase (TYMP), also known as platelet-derived endothelial cell growth factor, plays an important role in platelet activation in vitro and thrombosis in vivo by participating in multiple signaling pathways. Platelets are a major source of TYMP. Since platelet-mediated clot formation is a key event in several fatal diseases, such as myocardial infarction, stroke and pulmonary embolism, understanding TYMP in depth may lead to uncovering novel mechanisms in the development of cardiovascular diseases. Targeting TYMP may become a novel therapeutic for cardiovascular disorders. In this review article, we summarize the discovery of TYMP and the potential molecular mechanisms of TYMP involved in the development of various diseases, especially cardiovascular diseases. We also offer insights regarding future studies exploring the role of TYMP in the development of cardiovascular disease as well as in therapy.
机译:我们最近发现胸苷磷酸化酶(TYMP),也称为血小板衍生的内皮细胞生长因子,通过参与多个信号通路在体外体外和血栓形成的重要作用。 血小板是TYMP的主要来源。 由于血小板介导的凝块形成是几种致命疾病的关键事件,例如心肌梗死,中风和肺栓塞,理解为期间隔可能导致揭示心血管疾病发展的新机制。 靶向TYMP可能成为心血管障碍的新型治疗性。 在本综述文章中,我们总结了对TYMP的发现以及涉及各种疾病的发展的潜在分子机制,特别是心血管疾病。 我们还提供有关未来研究的见解,探讨了TYMP在心血管疾病发展中的作用以及治疗方面的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号